Analyst: Darzalex sales figures could result in Genmab upgrade

Sales of the Genmab-developed drug Darzalex, which is in-licensed to Jonhson & Johson, have gone so well in the third quarter that one analyst thinks a guidance upgrade from Genmab could likely be on its way.

BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN

Published: 19.10.21 at 15:33

The bone marrow cancer treatment Darzalex exceeded analysts' third quarter sales expectations with around DKK 850m.

The total market sales from the Johnson & Johnson-owned Janssen, which obtained Darzalex through an in-licensing agreement, could very well end up also exceeding the USD 5.6-5.9bn estimate that Genmab has included in its 2021 guidance.

Already a subscriber? Log in.

Read the whole article

Get 14 days free access.
No credit card required.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

"Real world" patient data documents the long-term effects of ALK vaccines

Data from ALK's React study, which is a retrospective real-world evidence study including more than 92,000 patients with respiratory allergies, have just been published in the journal The Lancet Regional Health – Europe. | Foto: ALK / PR

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.